All News
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of 2020: The COVID-19 Global Rheumatology Registry
What started out as online tweets and sharing newsfeed and case reports, has progressed to the formation of the COVID-19 Global Rheumatology Alliance, whose mission is to create an international rheumatology registry of patients affected by the disease in order to better understand the disease and guide clinicians in assessing and treating patients.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of 2020: A Rheumatologist’s Tips: Telemedicine in 6 Easy Steps
Ready for telemedicine/telerheumatology?
Once you and your patient agree on a virtual visit, the following suggestions may help facilitate the interaction. If you have the ability and the capacity, record the visit.
Links:
Best of 2020: Rheumatic Disease Drugs and COVID-19
We are in the early stages of trying to limit the morbid and mortal consequences of the corona virus pandemic of 2020. Not surprisingly, the recommendations designed to limit exposure and damage continually highlight the fact that the elderly and immunosuppressed may be amongst the most severely affected should they become infected with this virus.
This has led to a great deal of uncertainty by patients and providers about how rheumatic diseases and their treatments need to be specifically addressed.
Best of 2020: The Nine Lives of Hydroxychloroquine (Updated)
Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory arthropathy.
Read Article
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Filgotinib Bows Out of the RA Race in the USA
Gilead Sciences Inc announced yesterday that it has decided not to pursue the an rheumatoid arthritis (RA) indicatin for its once daily oral JAK inhibitor, filgotinib (also named Jyseleca).
Read Article
Consensus Recommendations on JAK Inhibitor Use
A steering committee and task force was convened to develop recommendations for the use of Janus kinase (JAK) inhibitors in the treatment of immune-mediated inflammatory diseases (IMID).
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
COVID Risks in Systemic Autoimmune Patients
There have been conflicting reports of whether rheumatic patients have greater risks once they are infected with COVID-19. This claims cohort analysis suggests a mixed picture.
Read Article
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)